All In Biotech

Drug Trial Radar · NCT04776226

Post-stroke Depression Treatment Effect on Stroke Recurrence

Impact of Pots-stroke Depression Treatment on Stroke Recurrence

Last checked: Nov 19, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,230

Actual

Start

Feb 11, 2017

Primary completion

Mar 10, 2018

Study completion Mar 30, 2019

Sponsor

Lead sponsor
Ege UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is not clear whether depresssion can predispose, or precipitate stroke recurrence in patients with stroke. We sought the relationship of post stroke depression with stroke recurrence.

Conditions

  • Stroke Recurrence
  • Cardiovascular Events
  • Depression

Interventions

  • CitalopramDrug

    Antidepressant use in patients with depression

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stroke recurrenceTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ege University

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.